population norm
Recently Published Documents


TOTAL DOCUMENTS

34
(FIVE YEARS 19)

H-INDEX

6
(FIVE YEARS 2)

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 7-7
Author(s):  
Mark C. Walters ◽  
John F. Tisdale ◽  
Markus Y. Mapara ◽  
Lakshmanan Krishnamurti ◽  
Janet L. Kwiatkowski ◽  
...  

Abstract Background: Sickle cell disease (SCD) is characterized by painful vaso-occlusive events (VOEs), progressive vasculopathy, hemolytic anemia, and organ damage resulting in frequent hospitalizations and decreased quality of life (QoL). The ongoing phase 1/2 HGB-206 study is evaluating the efficacy and safety of LentiGlobin for SCD (bb1111) gene therapy and has demonstrated complete resolution of severe VOEs, near-normalization of key hemolysis markers, and normalization of total hemoglobin up to 24 months post-LentiGlobin infusion in Group C. In addition, LentiGlobin for SCD also showed clinically meaningful improvements in QoL in adult patients. Here we present patient-reported QoL outcomes up to 24 months post-LentiGlobin infusion in Group C of the HGB-206 study. Methods: Patients (≥12-≤50 years of age) with severe SCD and recurrent severe VOEs underwent plerixafor mobilization and apheresis followed by myeloablative busulfan conditioning and LentiGlobin infusion. In addition to laboratory and clinical assessments, patients were monitored for patient-reported outcomes (PROs) at baseline and every 6 months post-infusion through Month 24 using PRO Measurement Information System (PROMIS)-57, a QoL-monitoring tool that has been validated in SCD. PROMIS-57 uses a collection of short forms to assess 7 PROMIS domains of relevance to patients' physical, mental, and social wellbeing (Depression, Anxiety, Pain Interference, Fatigue, Sleep Disturbance, Physical Function, Satisfaction with Participation in Social Roles) as well as a 0-10 Pain Intensity numeric rating scale (NRS). Available data were analyzed for 25/35 Group C patients (median age: 25 [19-38]; 40% female) who completed PROMIS-57 assessments at baseline with up to 24 months of follow-up as of February 17, 2021. For each domain, patients from the overall population were stratified into 2 subgroups depending on whether their baseline score was "better or near" or "worse" than the population norm, to account for potential differences over time in QoL changes relative to baseline status, and their means and standard deviations were plotted over time. The US general population norm is a standardized T-score of 50 for all domains and a 2.6 for Pain Intensity NRS. Meaningful change, a minimal response deemed meaningful to the patient, was interpreted at group level as at least a 5-point change from baseline for domains and a 2-point change for the NRS, as based on PROMIS guidelines and published literature. Results: In general, patients with baseline scores "worse" than the population norm reported improvements in all domains at Month 6 up to Month 24. Of note, mean pain interference decreased from 64.2 (n=16) to 44.5 (n=5), pain intensity decreased from 6.5 (n=15) to 1.8 (n=5) from baseline to Month 24 and fatigue decreased from 64.6 (n=8) to 46.9 (n=1) from baseline to Month 18, respectively (Figure). In patients with baseline scores "better or near" population norm, scores generally remained stable through Month 24. For example, mean pain interference scores were 46.4 (n=8) and 45.9 (n=4), pain intensity scores were 2.0 (n=9) and 2.8 (n=4), and fatigue scores were 47.7 (n=16) and 43.4 (n=9) at baseline and last visit, respectively. When considering mean differences, values for patients overall showed meaningful change in all domains and the Pain Intensity NRS, with the exception of Anxiety. Expected variability due to the small sample size limits interpretation. Mean values over time will be presented for all domains. Summary: In Group C of the HGB-206 study, patients with baseline scores "worse" than population norm had improved scores across all PROMIS-57 domains that were established early post-infusion and sustained up to Month 24. Patients with baseline scores "better or near" population norm were stable, and not worse up to Month 24. Mean values for patients overall indicate meaningful change at latest follow-up for all domains and Pain Intensity NRS, with the exception of Anxiety. These data show LentiGlobin for SCD not only improved hematologic parameters and resulted in complete resolution of severe VOEs, as presented elsewhere, but also provide sustained and clinically meaningful QoL benefit for patients. Continued follow-up and analysis of patient-reported outcomes is needed to evaluate the long-term impact of LentiGlobin for SCD. Figure 1 Figure 1. Disclosures Walters: Vertex pharmaceuticals: Consultancy; BioLabs, Inc: Consultancy; Ensoma, Inc.: Consultancy; AllCells, Inc: Consultancy. Kwiatkowski: Silence Therapeutics: Consultancy; Sangamo: Research Funding; Bioverativ: Research Funding; Apopharma: Research Funding; Bristol Myers Squibb: Consultancy; Imara: Consultancy, Research Funding; Celgene: Consultancy; Agios: Consultancy; bluebird bio,Inc.: Consultancy, Research Funding. Aygun: Patient Centered Outcomes Research Institute: Research Funding; bluebird bio, Inc.: Membership on an entity's Board of Directors or advisory committees, Research Funding; National Heart, Lung, Blood Institute: Research Funding; National Institute of Nursing Research: Research Funding; Global Blood Therapeutics: Consultancy. Gallagher: bluebird bio, Inc.: Current Employment, Current equity holder in publicly-traded company. Zhang: bluebird bio, Inc.: Current Employment, Current equity holder in publicly-traded company. Ho: bluebird bio, Inc.: Current Employment, Current equity holder in publicly-traded company. Thompson: Graphite Bio: Research Funding; Agios: Consultancy; Novartis: Research Funding; Global Blood Therapeutics: Current equity holder in publicly-traded company; Beam: Consultancy; CRISPR Therapeutics: Research Funding; Celgene/BMS: Consultancy, Research Funding; Biomarin: Research Funding; Baxalta: Research Funding; bluebird bio, Inc.: Consultancy, Research Funding; Vertex: Research Funding; Editas: Research Funding. Kanter: Fulcrum Therapeutics, Inc.: Consultancy; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Forma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Agios: Honoraria, Membership on an entity's Board of Directors or advisory committees; Beam: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Graphite Bio: Consultancy; GuidePoint Global: Honoraria; Fulcrum Tx: Consultancy.


2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Sigrid Boczor ◽  
Marion Eisele ◽  
Anja Rakebrandt ◽  
Agata Menzel ◽  
Eva Blozik ◽  
...  

Abstract Background The implementation of care concepts fitting the needs of patients with chronic heart failure (HF) remains challenging. In this context, psycho-emotional well-being is not routinely assessed, and under-researched despite indications that it is of great relevance for, e.g., acceptance, adherence, and prognosis. The aim of this study was to observe clinical characteristics for their prognostic utility in HF patients, and to compare the patients’ health-related quality of life (QoL) with German population norm values. Methods The current post-hoc analysis was performed on data collected amongst participants of the RECODE-HF study who had fully answered the EQ-5D-5L™ items at both baseline and 12 months (n = 2354). The status in the patients’ self-assessment items, EQ-5D visual analog scale (VAS) and EQ-5D index was categorized into worse/unchanged/improved. General linear mixed models (GLMM) with logit link were applied. Subgroups included 630 patients (26.8%) screened positive and 1724 patients (73.2%) screened negative for psychosocial distress (PSD). Results The 12-months change in EQ-5D index, generally resulting from change in individual EQ-5D items, additionally associated not only with high NYHA class but sociodemographics (employment/living alone/GP practice years) (96.2% correctly classified in GLMM). The 12- months change in individual QoL aspects showed associations with age*NYHA, gender, body-mass index, and comorbidities dyslipidemia, myocardial infarction, asthma/chronic pulmonary disease. Important social roles were reflected in particular when HF patients lived alone or the doctor mentioned to the patient that the patient had HF. Patients with/without PSD differed in some sociodemographic and clinical parameters. However, no influence of PSD could be demonstrated in the 12-month follow-up of the EQ-5D-5L™. Nonetheless, comparison of the 12-months QoL with general German population norm values by age groups < 75 years and 75+ showed markedly health restrictions in HF patients in all EQ-5D-5L™ aspects. Conclusion Our analysis revealed different prognostic factors primarily associated with change of burden in different QoL aspects in HF patients. In GP practice it is important to consider in addition to the overall day-related VAS all the individual health-related QoL aspects to take a holistic view of the patient, as well as to pay particular attention to the interrelation of individual characteristics.


PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0256142
Author(s):  
Arne Søraas ◽  
Karl Trygve Kalleberg ◽  
John Arne Dahl ◽  
Camilla Lund Søraas ◽  
Tor Åge Myklebust ◽  
...  

Long-COVID-19 is a proposed syndrome negatively affecting the health of COVID-19 patients. We present data on self-rated health three to eight months after laboratory confirmed COVID-19 disease compared to a control group of SARS-CoV-2 negative patients. We followed a cohort of 8786 non-hospitalized patients who were invited after SARS-CoV-2 testing between February 1 and April 15, 2020 (794 positive, 7229 negative). Participants answered online surveys at baseline and follow-up including questions on demographics, symptoms, risk factors for SARS-CoV-2, and self-rated health compared to one year ago. Determinants for a worsening of self-rated health as compared to one year ago among the SARS-CoV-2 positive group were analyzed using multivariate logistic regression and also compared to the population norm. The follow-up questionnaire was completed by 85% of the SARS-CoV-2 positive and 75% of the SARS-CoV-2 negative participants on average 132 days after the SARS-CoV-2 test. At follow-up, 36% of the SARS-CoV-2 positive participants rated their health “somewhat” or “much” worse than one year ago. In contrast, 18% of the SARS-CoV-2 negative participants reported a similar deterioration of health while the population norm is 12%. Sore throat and cough were more frequently reported by the control group at follow-up. Neither gender nor follow-up time was associated with the multivariate odds of worsening of self-reported health compared to one year ago. Age had an inverted-U formed association with a worsening of health while being fit and being a health professional were associated with lower multivariate odds. A significant proportion of non-hospitalized COVID-19 patients, regardless of age, have not returned to their usual health three to eight months after infection.


2021 ◽  
Vol 13 (2) ◽  
pp. 206-222
Author(s):  
Ľubica Ilievová ◽  
Slavka Demuthova ◽  
Marta Vavrova ◽  
Nikoleta Poliakova

Preparation for the profession of a nurse requires, in addition to knowledge, the development of specific skills; many of them are primarily connected to cognitive abilities. In the context of effective education, one of the key facts is to recognise the intelligence structure of nursing students. The aim of the research was to analyse the intelligence structure in nursing students, to compare scores in individual areas of intelligence with the norm, to identify problematic areas of intelligence, and to suggest possibilities for intervention in education. The research sample consisted of 266 women aged 19 to 43 years old (average age = 20.10 years) - current students of the study field of nursing at the bachelor's degree. Data collection was carried out in the years 2014 - 2019. To measure the structure of intelligence, a standardized IST-70 questionnaire was used, focusing on two meta constructs - reasoning and memory. Subtests of numerical, verbal, and figural intelligence were analysed within the meta construct of reasoning. The value of the gross score of the total intelligence level of the examined group (M = 84.95; SD = 19.87) is comparable (t = -1.58; sig. = 0.114) with the population norm (M = 87; SD = 25). The research sample of nursing students scored statistically significantly higher in the meta construct of memory (t = 7.84; sig. = 0.000) and significantly lower in the meta construct of reasoning (t = -3.876, sig. = 0.000). The most significant deficits were present in figural and numerical intelligence. In view of the results achieved, we recommend introducing interventions in the area of training future nurses, which should be aimed at compensating for deficits in figural and numerical intelligence.


2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
I Chaikovsky ◽  
A Popov ◽  
D Fogel ◽  
A Kazmirchyk

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Academy of Science of Ukraine Background Electrocardiogram (ECG) is still the primary source for the diagnostic and prognostic information about cardiovascular diseases. The concept of "normal ECG" parameters is crucial for the reliable diagnosis, since it provides reference for the ECG under examination. With the development of new methods and tools for ECG feature extraction and classification based on artificial intelligence (AI), it becomes possible to identify subtle changes in the heart activity to detect  possible abnormalities at the early stage.  The challenge of this work is to identify the deviations in  ECG of clinically healthy persons  from the conditional "population" norm . Methods The normal ECG is described as a feature vector composed of the time-magnitude parameters of signal-averaged ECG (SAECG). To define the subjects that possibly have variations from the "population" norm, the outlier detection approach is proposed: first the cloud of the vectors , constructed from the set of normal ECG"s , obtained from  young, clinically similar healthy persons  was created in feature space. Then, a particular ECG is considered deviant and requires the attention of the clinician when it is considered an outlier of the cloud of normal ECGs. In the experiment, SAECGs from the group of 139 young subjects (male, age 18-28  years) with no reported cardiovascular problems are used to extract 34 features from SAECG leads (magnitudes and durations of ECG waves, duration of ECG segments, etc.). ECGs were routinely previewed by qualified physicians, and no obvious anomalies were noticed. The Isolation Forest anomaly detection method is used with variable numbers of trees and different contamination parameters.  Results The ratio of outliers were changed from 5 to 10% (7-12 subjects) with various numbers of estimator trees. Seven outlier SAECGs were repeatedly appearing for various settings. Out of these, 4 subjects were the oldest persons in group examined , and 3 others had a rare ventricular premature beats during routine ECG examination. Conclusion The proposed method is promising for application in routine and express ECG tests since it is able to quantify the subtle deviations from the normal ECG group.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 10-10
Author(s):  
Julie Kanter ◽  
John F. Tisdale ◽  
Markus Y Mapara ◽  
Janet L. Kwiatkowski ◽  
Lakshmanan Krishnamurti ◽  
...  

Background In patients with sickle cell disease (SCD), health-related quality of life (HRQoL) is worse than in the general population and comparable or worse than in patients with other chronic or painful diseases such as cystic fibrosis or cancer. Targeting SCD pathophysiology may significantly improve HRQoL in addition to clinical outcomes. In the ongoing phase 1/2 HGB-206 Study (NCT02140554), which evaluates the safety and efficacy of LentiGlobin for SCD (bb1111) gene therapy (GT), the most recently treated cohort of patients (Group C) have demonstrated improvements in laboratory assessments, including a trend toward normalization in key hemolysis markers and improvements in total hemoglobin values, and near resolution of vaso-occlusive crises and acute chest syndrome (ACS), suggesting a fundamental effect on sickle cell pathophysiology. Patient-reported HRQoL outcomes through 12 months post-treatment are presented here. Methods Patients (≥12 and ≤50 years of age) with SCD and history of stroke or severe vaso-occlusive events, including acute episodes of pain and ACS, were enrolled. CD34+ cells collected by plerixafor mobilization/apheresis were transduced with BB305 lentiviral vector. LentiGlobin was infused following myeloablative busulfan conditioning. In addition to laboratory and clinical assessments, patients were monitored for patient-reported outcomes (PROs) using the PRO Measurement Information System (PROMIS)-57. PROMIS-57 assesses HRQoL using collection of short forms containing 8 questions for each of the 7 PROMIS domains (Depression, Anxiety, Pain Interference, Fatigue, Sleep Disturbance, in which a lower score denotes improvement, and Physical Function, Satisfaction with Participation in Social Roles, in which a higher score denotes improvement) and a 0-10 Pain Intensity numeric rating scale (NRS). PROMIS-57 has been validated in patients with SCD. Data were analyzed for ten Group C patients who had at least 12 months of follow-up and had completed PROMIS-57 assessments as of March 3, 2020. For each domain, patients were stratified into 2 sub-groups based on baseline scores and population norm (i.e., baseline scores "better" than or near the population norm and baseline scores "worse" than the population norm). The stratification was built upon the premise that patients with baseline scores "better" or near the population norm would not be expected to improve. The US general population norm was 2.6 for Pain Intensity and a T-score of 50 for all other domains. The minimal clinically importance difference (2-point difference for pain intensity NRS and 5-point difference for other domains) was selected based on the PROMIS guidelines and literature. Results Patients who had baseline scores "worse" than the population norm reported improvements in all domains at Month 6, which were sustained through Month 12. These patients reported clinically meaningful improvement in 6/8 domains; mean T-scores at baseline and Month 12 were 6 and 2.4 for Pain Intensity (n=5); 63 and 48 for Pain Interference (n=7); 62 and 48 for Anxiety (n=3); 62 and 44 for Depression (n=4); 39 and 60 for Satisfaction with Social Roles (n=5); and 40 and 56 for Physical Function (n=4), respectively. Only 1 patient was included in the analysis of Fatigue and Sleep Disturbance domains, thereby limiting the conclusions in these 2 domains (Figure 1). Patients who had baseline scores that were "better" or near than the population norm reported clinically meaningful improvements in the Physical Function (n=6) and Fatigue domains (n=9); mean scores at baseline and Month 12 were 49 and 55 for Physical Function and 50 and 43 for Fatigue, respectively. Among patients in this sub-group, Pain Intensity (n=5) and Pain Interference (n=3) scores were stable from Month 6 through Month 12; there was no clinically meaningful change for the Anxiety (n=7) and Depression (n=6) domains, however, worsening was observed in the Satisfaction with Social Role (n=4) and Sleep Disturbance (n=9) domains (Figure 1). Summary LentiGlobin for SCD GT improved HRQoL in all domains of PROMIS-57 for patients whose baseline scores were "worse" than the population norm, including clinically meaningful improvements in all evaluable (6/8) domains. Larger sample sizes are required to clarify the impact of LentiGlobin for SCD for some PROMIS-57 domains. Disclosures Kanter: SCDAA Medical and Research Advisory Board: Membership on an entity's Board of Directors or advisory committees; AGIOS: Membership on an entity's Board of Directors or advisory committees; BEAM: Membership on an entity's Board of Directors or advisory committees; Jeffries: Honoraria; Cowen: Honoraria; Wells Fargo: Honoraria; NHLBI Sickle Cell Advisory Board: Membership on an entity's Board of Directors or advisory committees; bluebird bio, inc: Consultancy, Honoraria; Novartis: Consultancy; Sanofi: Consultancy; Medscape: Honoraria; Guidepoint Global: Honoraria; GLG: Honoraria. Kwiatkowski:Terumo Corp: Research Funding; Imara: Consultancy; Celgene: Consultancy; Agios: Consultancy; bluebird bio, Inc.: Consultancy, Research Funding; Novartis: Research Funding; Sangamo: Research Funding; Apopharma: Research Funding; Bristol Myers Squibb: Consultancy. Chen:bluebird bio, Inc.: Consultancy. Gallagher:bluebird bio, Inc.: Current Employment, Other: Ownership Interest and Salary. Ding:bluebird bio, Inc.: Current Employment, Other: Salary. Goyal:bluebird bio, Inc.: Current Employment, Other: Ownership Interest and Salary. Paramore:bluebird bio, Inc.: Current Employment, Other: Ownership Interest and Salary. Thompson:bluebird bio, Inc.: Consultancy, Research Funding; BMS: Consultancy, Research Funding; CRISPR/Vertex: Research Funding; Baxalta: Research Funding; Biomarin: Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Walters:AllCells, Inc: Consultancy; Veevo Biomedicine: Consultancy; Editas: Consultancy.


2020 ◽  
Vol 137 ◽  
pp. 161-170
Author(s):  
Sandra Nolte ◽  
Annika Waldmann ◽  
Gregor Liegl ◽  
Morten Aa Petersen ◽  
Mogens Groenvold ◽  
...  

2020 ◽  
Vol 25 (6) ◽  
pp. 3688
Author(s):  
M. M. Kayumova ◽  
M. Yu. Akimov ◽  
V. V. Gafarov

Aim. To assess age and sex characteristics of hostility among the population of a medium urban Siberian city.Material and methods. Cross-sectional epidemiological studies were carried out among men and women aged 25-64 years in Tyumen; the response rate was 85,0% among men and 70,3% among women. To assess hostility, the algorithms of the WHO program MONICA-Psychosocial were used. There were low, moderate and high levels of hostility. Low hostility was considered the population norm.Results. In the open population of a medium urban Siberian city, an unfavorable data was found for the hostility prevalence. High levels of hostility were revealed in both men and women in the whole age range. However, a high level of hostility prevailed among women compared to general population values by age and in four decades of life.Conclusion. The data obtained will help to develop evidence-based prevention programs based on the effects on psychosocial factors taking into account age and sex characteristics.


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 3614-3614
Author(s):  
Shivaani Kummar ◽  
Cornelis M. Van Tilburg ◽  
Catherine M. Albert ◽  
Jordan Berlin ◽  
Anna F. Farago ◽  
...  

3614 Background: NTRK gene fusions occur in diverse tumor types in adults and children. The selective TRK inhibitor, larotrectinib, has shown high response rates, durable disease control, and a favorable safety profile in patients (pts) with TRK fusion cancer. We report an expanded quality of life (QoL) analysis for pts treated with larotrectinib. Methods: QoL data were collected in two trials of larotrectinib in pts with TRK fusion cancer using EORTC QLQ-C30 (adults) and PedsQL (children) questionnaires, and were analyzed descriptively and longitudinally. EORTC QLQ-C30 global health scores (GHS) and PedsQL total scores range from 0 to 100, with higher scores indicating better QoL. We calculated the proportion of pts with normal/above and below normal QoL scores compared to values in the literature for the US general population. Results: By July 2019, 126 pts with TRK fusion cancer (74 adults, 24 children ≥2 yrs, and 28 infants <2 yrs) had received larotrectinib and completed baseline (BL) and ≥1 post-BL questionnaire. Most pts had clinically meaningful QoL improvements that reached or exceeded the minimally important difference (Table); a positive change from BL was also seen in infants: mean best change of 12.0 (SD 13.8). Of 52 adults with BL EORTC QLQ-C30 GHS at or above the population norm, 51 remained in this category on treatment and 1 moved into the below normal category. Of 22 adults with BL scores below the population norm, 20 moved into the normal/above normal category. All 9 children aged ≥2 yrs with BL PedsQL scores at or above the population norm remained in this category on treatment. Of 15 children with BL scores below the population norm, 10 moved into the normal/above normal category. Sustained QoL improvements (change from BL ≥0) occurred by 2 months of treatment in 69% of adults and 75% of children. Median duration of sustained improvement in EORTC QLQ-C30 GHS and PedsQL total score was 12.0 months (range 1.7–20.3) and not estimable (range 1.1–23.0), respectively. Conclusions: Adults and children with TRK fusion cancer treated with larotrectinib had rapid, clinically meaningful, and sustained improvements in QoL. Clinical trial information: NCT02576431, NCT02637687 . [Table: see text]


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e20053-e20053
Author(s):  
Matthew Roger LeBlanc ◽  
Sheryl Zimmerman ◽  
Mariam Kayle ◽  
Thomas William LeBlanc ◽  
Kathryn Elizabeth Hudson ◽  
...  

e20053 Background: Fatigue is a common and distressing effect of cancer and its treatment. Prior research suggests fatigue persists long after diagnosis and treatment in non-Hodgkin lymphoma (NHL) survivors. This study aimed to identify distinct trajectories of fatigue in NHL survivors and predictors of trajectories that could inform clinical care. Methods: Our secondary analysis used data from a longitudinal study of NHL survivors (n = 886) at least 2 years post-diagnosis. Fatigue was measured using the SF-36 vitality subscale across three time points. Prior literature informed the selection of baseline demographic (e.g. age, gender, race) and disease characteristics [e.g. NHL type, comorbidities, post-traumatic stress disorder (PTSD)] explored as possible predictors of fatigue trajectories. We used group-based trajectory modeling to identify distinct groups of patients experiencing similar patterns of fatigue. Variables significant in bivariate analysis were included in a stepwise multinomial logistic regression to identify factors predictive of group membership. Results: We identified four distinct trajectories that suggest levels of fatigue persist unchanged over time. The Low Fatigue Group (15.6%) experienced less fatigue than the general population. The Population Norm Group (42.5%) experienced a similar level of fatigue to the general population mean. The Significant Fatigue Group (27.5%) experienced fatigue levels almost one standard deviation worse than the general population. The Worst Fatigue Group (14.3%) experienced fatigue almost two standard deviations worse than the population norm. PTSD symptoms and comorbidity scores were predictive of levels of fatigue over time. Greater age at diagnosis increases the odds survivors experienced worse fatigue than the population mean (Table). Conclusions: Levels of fatigue experienced early in an NHL patients’ disease trajectory may persist for many years. Higher levels of PTSD symptoms and comorbidities were predictive of worse fatigue over time. Early interventions addressing PTSD symptoms and comorbidities may improve long term fatigue outcomes. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document